The Joint Committee on Vaccination and Immunisation (JCVI) is currently reviewing evidence on the impact and cost-effectiveness of extending the human papillomavirus vaccination programme to adolescent boys. This includes mathematical modelling being undertaken by Public Health England.
In February 2018 JCVI agreed that it needed to see the results of the independent peer review of the modelling work, and the additional analyses being undertaken, before concluding its advice. The JCVI further agreed that legal advice should be obtained in response to stakeholder correspondence.
Once JCVI has reached a decision, the Committee’s advice will be published most likely in the form of a statement alongside the minutes of the relevant meeting. The JCVI will not be in a position to conclude its advice until the required modelling, peer review and legal advice has been considered. This work will continue through 2018 and timeframes for JCVI concluding its advice are dependent on completion of the analyses requested.